- Home
- PSHG vs COCP Comparison
PSHG vs COCP Comparison
Compare PSHG & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | COCP |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 21.6M |
| IPO Year | 2010 | 2011 |
Fundamental Metrics
Financial Performance| Metric | PSHG | COCP |
|---|---|---|
| Price | $1.63 | $1.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.75 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 66.2K | 42.9K |
| Earning Date | 11-24-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | $48.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.76 |
| 52 Week High | $2.58 | $2.03 |
Technical Indicators
Market Signals| Indicator | PSHG | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 37.60 |
| Support Level | $1.63 | $0.98 |
| Resistance Level | $1.89 | $1.11 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.85 | 9.14 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.